A new path to hope
Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on improving the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.
 |
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death
read more |
 |
Focus: the spheno-palatine ganglion
Two small nervous centers located above the roof of the mouth near the sinuses
read more |
|
July 15, 2014
ImpACT24 Interim Results
The Data Safety Monitoring Board (the "DSMB") for BrainsGate's study examined the interim results and deterimined the results support the continuation of the study > full story
January 1, 1970
> full story
|